The selective retention and expression of the E6-E7 region of human papillomavirus (HPV) types 16 and 18 in cervical carcinomas suggests that these viral sequences play a role in the development of genital neoplasia. Each of three possible gene products, E6, E6*, and E7, from this region of HPV-18 were examined for transforming properties in several types of rodent cells. We have found that in immortalized fibroblasts, both E6 and E7 (but not E6*) are capable of inducing anchorage-independent growth. In rat embryo cells, the HPV-18 E7 open reading frame was an effective immortalizing agent and complemented an activated ras oncogene for transformation. In both immortalized and primary cells, transformation was observed when the HPV-18 sequences were expressed from either the HPV-18 promoter or a heterologous promoter. The E6-E7 region is not, however, the sole transforming domain of HPV-18, since another portion of the early region, possibly E5, also exhibited transforming capability in immortalized fibroblasts. The development of human cervical carcinomas may therefore involve a series of steps involving multiple viral and cellular gene products.
Papillomaviruses are a group of small DNA viruses which induce a variety of proliferative lesions in the skin and internal mucosa. More than 50 types of human papillomaviruses (HPV) have been identified, with the majority found in benign lesions such as warts and papillomas (7, 29, 44 ). However, a subset of these viruses are found in over 90% of malignant carcinomas of the genital tract. Of these HPVpositive carcinomas, the majority contain type 16 (HPV-16), and HPV-18 is the next most common type (6, 14, 30) . Although this evidence strongly suggests a role for HPV infection in the development of genital cancer, other genetic or environmental factors are also probably involved (7, 29) .
In cervical tumor cell lines, the viral genome is frequently integrated into random sites of host chromosomes, whereas benign lesions usually contain multiple copies of viral episomes (3, 15, 34, 35, 37) . In the majority of these tumors, the viral integration site is within orjust upstream of the E2 open reading frame (ORF). Since E2 products of a number of papillomaviruses, including HPV-16 and HPV-18 have been shown to be both positive and negative regulators of viral transcription (8, 12, 18, 19, 22, 23, 27, 31, 39) , the selective integration that has occurred in carcinomas may result in deregulation of HPV expression. The most abundant viral transcripts in carcinoma cells initiate within the noncoding region, terminate in cellular sequences, and have the potential to encode each of the E6 and E7 ORFs, as well as a splice product, E6* (3, 34, 37) . The E6 and E7 proteins, but not E6*, have been identified in cervical carcinoma lines (1, 4, 36, 38) , suggesting that either or both of these proteins are involved in the development of malignant disease.
Papillomavirus transforming functions have been best characterized in bovine papillomavirus type. 1, in which transforming activity has been localized to the E6 and E5 ORFs (33, 42) . Recently, several groups have reported that HPV-16 sequences transform immortalized rodent cells in vitro (24, 40, 43) . The E7 ORF of this virus cooperates with an activated ras gene in the transformation of primary cells (28, 32) and by itself is an effective immortalizing agent (25) .
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We have previously reported that a major transforming function of HPV-18 in immortalized fibroblasts is encoded by the E6-E7 region (5) . In the present study, we have examined each of the E6 and E7 ORFs of and the remainder of the early region for the ability to confer anchorage-independent growth and tumorigenesis in several types of cultured cells. Both of the E6 and E7 ORFs (but not E6*) were found to encode independent transforming functions in immortalized cells. We also demonstrate that HPV-18 E7, like E7 of HPV-16, cooperates with an activated ras oncogene in transforming primary cells. This suggests that the two most common HPV types found in genital carcinomas may function through a similar mechanism of transformation in vivo. Another portion of the HPV-18 early region, perhaps E5, is also shown to be capable of transforming immortalized fibroblasts.
MATERIALS AND METHODS
Plasmids. The plasmids used for transformation experiments are shown in Fig. 1 and 2 . The construction and transforming activity of pl8PEpolyA (Fig. 1B) has been previously reported (5) . Mutations were created in the different ORFs of pl8PEpolyA by insertion of oligonucleotide linkers into various restriction sites. Two types of linkers which result in different kinds of mutations were used: a translation termination linker (TTL), TTAAGTTAA CTTAA, was used to create nonsense mutations, while linkers which alter the reading frame were used to create frameshift mutations (FS). The restriction sites used, the affected ORFs, and the resulting plasmids which contain the mutagenized sequences are as follows: BamHI, both E6 and E6*, p18PEBamFs and pl8PEBamTTL; SphI, E6, pl8
PESphFS and pl8PESphTTL; and HincII, E7, p18PEHincFS and pl8PEHincT-rL. An and ligated to linkers. Linkers were ligated directly to the blunt ends of HincII-digested DNA. Plasmids which contain FS mutations in both of the E6 and E7 ORFs were constructed by exchanging appropriate fragments of pl8PEBamFS, pl8PESphFS, and pl8PEHincFS. The affected ORF in each of the resulting double-site mutant plasmids is as follows: E6 and E7, pl8PESph/Hinc; and E6 and E6*, and E7, pl8PEBam/Hinc. The 6.2-kilobase (kb) PstI fragment of HPV-18, which contains the entire early region, was inserted into the PstI site of pUC9 to generate pl8-Pst (Fig. 1C) . This plasmid carries an intact noncoding region and E6-E7 region identical to that of pl8PEpolyA but also contains the entire El, E2, E4, and E5 ORFs and putative early polyadenylation sequence. pl8-PstB/H was constructed by replacing the EcoRI fragment of pl8PEBam/Hinc, which carries the simian virus 40 (SV40) polyadenylation sequences, with a fragment of pl8Pst from the EcoRI site in El to an EcoRI site in the polylinker of pUC9. The E6-E7 region of p18-PstB/H is thus identical to that of pl8PEBam/Hinc with FS linker insertions in E6, E6*, and E7, whereas all other sequences are identical to those of p18-Pst.
Expression vectors for each of the E6 and E7 ORFs were constructed by inserting fragments with each ORF into a plasmid containing the human metallothionein "A transcriptional-regulatory region (Fig. 2) . This plasmid, pHSI, consists of human metallothionein IIA sequences from -770 to +69 and has a unique BamHI site located 70 bp 3' to the start of transcription (21) . The E6 ORF was contained on a 540-bp Avall fragment that had been filled in by using the Klenow fragment of Escherichia coli DNA polymerase I, whereas a 410-bp HaeIII-Sau3A fragment was used for the E7 ORF. BglII oligonucleotide linkers were added to the blunt ends of each fragment for cloning into the BamHI site of pHSI. An expression plasmid which contains both E6 and E7 was constructed by inserting an XbaI fragment of HPV-18 ( Fig.  1A) into the XbaI site of p18MTE6. Translation termination linkers, as described above, were inserted into the BamHI [11] ), which was made blunt and ligated to BgII linkers for cloning. BgIII linkers were added to a HaeIII-Sau3A fragment (nt 510 to 920 [11] ) containing the E7 ORF. Both fragments were cloned into the BamHI site of pHSI (21) . An XbaI fragment from HPV-18 ( Fig. 1A) was inserted into p18MTE6 to make p18MTE6/E7. The SV40 early polyadenylation sequences of p18MTE6, p18MTE7, and pl8MTE6/E7 are contained on a 2.1-kb EcoRI fragment of pSV2cat (20) , whereas p18MTE7A carries SV40 early polyadenylation sequences on a BglII-BamHI fragment of an SV40 expression vector (see Materials and Methods). Not shown are analogous expression vectors in which E6 and E7 were mutagenized by insertion of translation termination linkers into the BamHl and Hincll sites, respectively ( Fig. 1 ). Restriction sites, in addition to those in Fig. 1 (20) were cloned into all expression plasmids except p18MTE7A. In p18MTE7A, the polyadenylation sequences were contained on a BglII-BamHI fragment of pKS, an SV40 expression vector derived from pKSV10 (Pharmacia, Inc., Piscataway, N.J.) by deletion of a 0.5-kb HindIII fragment in T antigen sequences (not shown).
Cell culture, transfections, and transformation assays. NIH 3T3 and Rat-1 cells were maintained and transfected as previously described (5) . Briefly, HPV-18 plasmids or control (pUC9 or pHSI) plasmids were transfected at a 10:1 ratio with either pRSVneo or pSV2gpt. First-passage rat embryo cells from Fisher rats (REFs) were obtained from M. A. Bioproducts, Walkersville, Md. REFs were transfected after the second passage as described for NIH 3T3 and Rat-1 cells (5) , except that a total of 55 pxg of DNA was used (25 ,ug each for HPV-18 plasmids and either pEJras or pUC9 and 5 ,ug of pRSVneo) and the G418 concentration was 300 ,ug/ml. After 1 to 2 weeks in selective media, resistant colonies were either pooled from an entire plate or individually cloned and expanded into cell lines. After the first passage of these lines, anchorage-independent growth was determined by plating the cells in 0.3% agarose. In most experiments, growth in soft agar was scored after 2 to 3 weeks for NIH 3T3 and Rat-1 cells and 1 week for REFs. To determine the life span of REF lines, we passaged cultures twice weekly at a ratio of 1:5. Representative NIH 3T3 transfected cell lines were injected (2 x 106 cells) into two to four subcutaneous sites of 3-to 6-week-old nulnu mice, and the animals were monitored for the appearance of tumors.
DNA and RNA analysis. Total cellular RNA was isolated (9) from subconfluent cultures of either pooled or individual colonies, whereas high-molecular-weight DNA of individual transfected lines was prepared as described previously (5) . Both Southern and Northern (RNA) blots were prepared and probed as described previously (5) .
RESULTS
Mutational analysis of the HPV-18 E6-E7 transforming region in immortalized cells. In cervical tumor cells, the most abundant HPV transcripts originate from the E6-E7 region and terminate with cellular polyadenylation signals (3, 15, 35, 37) . We have previously demonstrated that a plasmid (pl8PEpolyA) which mimics this state is sufficient to transform NIH 3T3 and Rat-i cells to an anchorage-independent state in the absence of morphological transformation or focus formation (5). pl8PEpolyA (Fig. 1B) contains the entire noncoding region, intact E6 and E7 ORFs, and truncated El ORF of HPV-18, as well as heterologous polyadenylation sequences. To identify which of three possible gene products (E6, E6*, or E7) from this region of HPV-18 encodes transforming activity, we introduced translation termination and frameshift mutations into each ORF. The resulting plasmids were then transfected with a selectable marker into NIH 3T3 and Rat-1 cells, and their transforming capabilities were determined in a manner identical to that described previously (5) . This assay involves random selection, cloning, and expansion of individual drug-resistant colonies into cell lines which are then tested for their ability to grow in 0.3% agarose. We have used the incidence of anchorage-independent lines induced by each construct as a measure of transforming ability.
The frequency at which NIH 3T3 and Rat-i lines exhibited anchorage independence following transfection of p18 PEpolyA and its derivatives is shown in Fig. 1 ) was cotransfected with a selectable marker into each cell line. After selection for drug resistance, individual colonies were chosen at random, expanded into cell lines, and plated in 0.3% agarose. The lines were considered positive for anchorage independence if more than 10% of the plated cells formed colonies of more than eight cells after 2 to 3 weeks in soft agar. The number of lines that were positive out of the total number tested are shown for each plasmid. ' The total number of cell lines transfected with FS and TTL mutations in each site are shown in parentheses. To determine whether the mutant derivatives of pl8PEpolyA and all of the expression vectors expressed E6-E7 RNA at similar levels, RNA from pooled colonies of three separate transfections with each plasmid was examined, and representative Northern blots are shown in Fig. 3 . The expression of E6-E7 sequences in cell lines transfected with plasmids containing each type of single-or double-site mutation was decreased two-to threefold relative to pl8PEpolyA (Fig. 3A) . However, cell lines containing each pl8PEpolyA mutant expressed comparable levels of RNA, and there was no obvious correlation between a mutated sequence and diminished expression. The reason for the increased expression of pl8PEpolyA over that of its mutant derivatives is presently unknown. In pooled cell lines transfected with the expression vectors (Fig. 3B) (Fig. 3) , the differences in soft-agar cloning efficiencies are not likely to be the result of differential expression. These results therefore provide further evidence that the E6 and E7 ORFs encode independent transforming functions but may differ in their oncogenic potency.
The E6-E7 region is not the sole transforming domain of HPV-18 in immortalized cells. To determine whether E6 and E7 are the only transforming genes present in the HPV-18 early region, we constructed and tested two additional plasmids p18-Pst and p18-PstB/H (Fig. 1C) . Although both of these plasmids contain a 6.2-kb fragment which encompasses the entire noncoding region, all early ORFs, and the putative early polyadenylation sequence of HPV-18, p18-PstB/H differs from p18-Pst only in the presence of linker insertions in the E6, E6*, and E7 ORFs. When p18-Pst was transfected into NIH 3T3 cells, 9 of 11 individual lines were transformed to anchorage independence (Table 1) . Interestingly, mutagenesis of the E6-E7 region in p18-PstB/H did not significantly affect transforming function, since four of five transfected lines exhibited anchorage independence (Table  1) . It is unlikely that the mutagenized E6-E7 sequences in p18-PstB/H encode residual transforming activity, since they contain the identical linker insertions which abolished the activity of pl8PEBam/Hinc (see above). The E6-E7 region therefore does not appear to be the only transforming domain expressed from the intact early region. By analogy to the transforming function of bovine papillomavirus type 1 E5 (33, 42), we suspect that an HPV-18 E5 gene may encode this additional transforming activity. In support of this, eight pl8Pst and pl8PstB/H lines examined contained an intact E5 ORF, and E5-specific RNA was expressed (data not shown).
Cooperation of HPV-18 sequences with a ras oncogene in the transformation of primary rodent fibroblasts. The E7 ORF of HPV-16, when expressed from strong heterologous promoters, has recently been shown to cooperate with an activated ras gene in the transformation of primary rodent cells (28, 32) . To determine whether the HPV-18 E6-E7 sequences also complement ras, second-passage REFs were cotransfected with pl8PEpolyA, pEJras (a plasmid which contains an activated human c-Ha-ras gene), and a plasmid carrying a selectable marker in four different experiments. After selection, a high frequency of the drug-resistant colonies from these transfections exhibited morphological transformation. In contrast, no morphologically altered colonies were observed in over 200 colonies derived from control transfections with pUC9 and EJras or when pl8PEpolyA was cotransfected with pUC9. The colonies transformed by pl8PEpolyA and ras were elongated, highly refractile, and poorly adherent, whereas pUC9-plus-ras or pl8PEpolyA-plus-pUC9 transfectants displayed a morphology similar to that of untransfected cells (Fig. 4) . Eight of the pl8PEpolyA-plus-ras morphological transformants were cloned and tested for anchorage-independent growth, and all formed large colonies (>100 cells) within 1 week after plating in 0.3% agarose (Table 3 ). In addition, all five transformants tested have been passaged 10 or more times and appear to be established cell lines. In contrast, none of six randomly chosen colonies derived from pUC9 and pEJras cotransfections were anchorage independent, and four colonies tested for immortalization all senesced before passage 5.
To identify which HPV-18 sequence mediates ras-cooperating activity, the mutant and expression constructs shown in Fig. 1 and 2 were cotransfected with pEJras and a selectable marker into REFs. When pEJras was cotransfected with any of the plasmids bearing an intact E7 ORF (p18PEBamFS, pl8PEBamTTL, p18PESphFS, pl8PESphTTL, p18MTE7A, and pl8MTE7), morphologically transformed colonies were observed at a frequency similar to that observed after cotransfection of pEJras and pl8PEpolyA. In contrast, morphologically transformed colonies were not b Expanded colonies were plated in 0.3% agarose at the first passage after cloning. If more than 1% of the plated cells were able to form foci in soft agar within 1 week, the clones were considered positive. The number of expanded colonies which were positive for anchorage-independent growth, versus the number tested with each pair of plasmids, is shown.
c Expanded colonies were passaged twice a week at a ratio of 1:5 and were considered immortalized if they survived 10 passages.
d ph-.L, p18MTE7A, or p18MTE7 (Table 3 ). The morphology of these transformants on plastic and in soft agar was similar to that of pl8PEpolyA-plus-pEJras transformants (Fig. 4) . Of 20 E7-plus-EJras transformants, representing at least three independent lines isolated following transfection of p18MTE7 and each kind of mutation in the BamHI and SphI sites, 19 have been continuously passaged more than 10 times without senescence or loss of morphological alterations (Table 3) . To ensure that these transformants contained and expressed both HPV-18 sequences and pEJras DNA, Southern and Northern analyses were performed on 14 different anchorage-independent lines. In all 14 lines, both the E6-E7 sequences of the HPV-18 plasmids and the coding sequences of EJras were intact and expressed (data not shown).
The ability of REFs expressing both EJras and HPV-18 E7 sequences to survive continuous passage suggests that they had become immortalized. To determine whether the HPV-18 E7 sequences alone were capable of immortalizing these cells, we cloned and continuously passaged six colonies each from transfections of p18MTE7, pl8MTE7Hinc, or pUC9.
None of the colonies transfected with either E7 plasmid exhibited a morphology substantially different from pUC9 transfectants. All six p18MTE7 colonies survived at least 10 passages, whereas senescence occurred before passage five in all pl8MTE7Hinc colonies and pUC9 colonies (data not shown). Northern and Southern analyses were performed on five of the p18MTE7 immortalized lines, and the E7 sequences were intact and expressed in all of them (data not shown). These results demonstrate that the HPV-18 E7 sequence, like HPV-16 E7, encodes an immortalizing activity which is capable of complementing the activity of a ras oncogene in the transformation of primary cells.
The absence of morphological transformation after cotransfection of either E7 mutant plasmids or p18MTE6 with pEJras (Fig. 4) 1 (2) and HPV-18 (20a) have been localized to the nucleus and nonnuclear membranes, whereas the E7 protein of HPV-16 was found only in the cytoplasm (38) . Consistent with its presence in the nucleus, a strong but nonspecific DNA-binding activity has been observed for the HPV-18 E6 protein (20a). Phelps et al. (32) have recently reported that the HPV-16 E7 encodes a transcriptional trans-activating activity, suggesting that at least a small fraction of the protein may localize to the nucleus. Interestingly, a small domain of E7 that is conserved in genital HPVs has been found to have significant homology to a sequence motif common to T antigen of papovaviruses, adenovirus Ela, and the v-myc and c-myc oncogenes (17, 32) . Recently, both SV40 T antigen and adenovirus Ela have been shown to form a specific complex with the cellular retinoblastoma protein (13, 41) , which is thought to be a tumor suppressor or regulator of cell growth (26) . Significantly, mutations in this conserved sequence which abolish the transforming activity of these viral proteins also abolish complex formation. Since T antigen, Ela, myc, and E7 all share the ability to complement ras as well as a conserved sequence domain, it is tempting to speculate that the transforming functions of all four types of proteins involve a common pathway for cell growth.
Although the E6 and E7 sequences of HPV-18 are capable of transforming cells in vitro, they do not appear to be the sole transforming genes present in the HPV-18 genome. This is suggested by experiments in which the transforming activity of the 6.2-kb PstI fragment was not affected by mutagenesis of the E6 and E7 sequences. Since the HPV-18 E5 ORF has some features in common with the bovine papillomavirus type 1 E5 sequence and the latter has transforming activity (33, 42) , we speculate that this sequence may encode the additional transforming activity. Because sequences other than E6 and E7 are not conserved in cervical carcinoma cells, it is unlikely that any other gene products are required for maintenance of the malignant phenotype. However, the additional transforming functions could be involved in the development of benign or preneoplastic lesions, in which the entire viral genome is generally present (15, 29) . In this case, the transforming activity of the E6-E7 sequences may be limited, perhaps by transcriptional repression by products of the E2 ORF. Consistent with this, Broker and co-workers have reported that the E6-E7 region of HPV-6 and HPV-11 in benign genital lesions is expressed at very low levels and that the HPV-11 E2 encodes a repressor of the E6 promoter (8, 10) . Similarly, the E6-E7 region is poorly expressed from plasmids containing either a permuted viral genome (5) or the 6.2-kb PstI fragment of the early region (M. Bedell, unpublished results). Once viral integration occurs and E2 is no longer expressed, E6-E7 transcription may be deregulated and the E6 and E7 proteins may play a significant role in the development of malignant lesions. However, epidemiological evidence demonstrates that other factors, which may involve the activation of cellular proto-oncogenes, are required in addition to HPV infection for the development of cervical carcinomas (7, 29) . Thus, several events involving both viral and cellular genes may be required for the development of malignant lesions of the genital tract.
